Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 14/20 | 0.55 |
| ▸ | PDE4A | P27815 | 4/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20269069 | 0.97 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12598497 | 0.95 | PGR (0.56) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22271500 | 0.93 | PGR (0.53) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5313889 | 0.84 | PGR (0.43) | PGRIP6K1 | |
| SCHEMBL9375869 | 0.83 | MAPK14 (0.49) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29622047 | 0.79 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5499005 | 0.79 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25399999 | 0.76 | PGR (0.58) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21912449 | 0.76 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11641485 | 0.76 | PGR (0.71) | PGRPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| WO-2018109271-A1 | NEW BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109271-A1 | NEW BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-06-21 | — | — | WO | disclosed |
| EP-3310772-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | Orion Corporation (FI) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203112-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203112-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | WO | disclosed |
| WO-2015092118-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092118-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | PGR 1184/4885PDE4A 1276/4885PDE4B 1550/4885 |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | PGR 1205/4885PDE4A 1285/4885PDE4B 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.